

Tuomas Mirtti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7398896/publications.pdf>

Version: 2024-02-01

74
papers

1,420
citations

361413

20
h-index

361022

35
g-index

78
all docs

78
docs citations

78
times ranked

2986
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. <i>Theranostics</i> , 2017, 7, 3824-3841.	10.0	167
2	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. <i>Lancet Oncology</i> , 2017, 18, 132-142.	10.7	124
3	Rac1 Nucleocytoplasmic Shuttling Drives Nuclear Shape Changes and Tumor Invasion. <i>Developmental Cell</i> , 2015, 32, 318-334.	7.0	75
4	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327.	1.9	74
5	Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. <i>FASEB Journal</i> , 2019, 33, 2858-2869.	0.5	59
6	Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0133552.	2.5	55
7	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. <i>Modern Pathology</i> , 2016, 29, 1565-1574.	5.5	43
8	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. <i>PLoS Medicine</i> , 2019, 16, e1002813.	8.4	43
9	Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. <i>Human Pathology</i> , 2013, 44, 310-319.	2.0	42
10	SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. <i>Scandinavian Journal of Urology</i> , 2018, 52, 313-320.	1.0	40
11	Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. <i>PLoS ONE</i> , 2015, 10, e0140671.	2.5	39
12	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. <i>European Journal of Epidemiology</i> , 2017, 32, 521-527.	5.7	36
13	Functional imaging with ¹¹ C-metomidate PET for subtype diagnosis in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2020, 183, 539-550.	3.7	36
14	Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 101-109.	0.4	31
15	PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance. <i>European Urology Focus</i> , 2018, 4, 867-873.	3.1	30
16	ITGB1-dependent upregulation of Caveolin-1 switches TGF β 2 signalling from tumour-suppressive to oncogenic in prostate cancer. <i>Scientific Reports</i> , 2018, 8, 2338.	3.3	29
17	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , 2019, 144, 1356-1366.	5.1	29
18	Adiponectin receptor agonist AdipoRon ameliorates renal inflammation in diet-induced obese mice and endotoxin-treated human glomeruli <i>ex vivo</i> . <i>Diabetologia</i> , 2021, 64, 1866-1879.	6.3	24

#	ARTICLE	IF	CITATIONS
19	Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. <i>International Journal of Cancer</i> , 2016, 139, 140-152.	5.1	23
20	Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. <i>Prostate</i> , 2019, 79, 1505-1513.	2.3	23
21	Repeat multiparametric MRI in prostate cancer patients on active surveillance. <i>PLoS ONE</i> , 2017, 12, e0189272.	2.5	23
22	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials). <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1556-1567.	3.4	22
23	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. <i>Oncolmmunology</i> , 2020, 9, 1761229.	4.6	22
24	Patient Experience of Systematic Versus Fusion Prostate Biopsies. <i>European Urology Oncology</i> , 2018, 1, 202-207.	5.4	20
25	Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0153745.	2.5	20
26	Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy. <i>Oncotarget</i> , 2018, 9, 31200-31213.	1.8	19
27	New prostate cancer grade grouping system predicts survival after radical prostatectomy. <i>Human Pathology</i> , 2018, 75, 159-166.	2.0	17
28	Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 713-726.	4.1	16
29	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 12682.	3.3	16
30	Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 231-246.	4.1	16
31	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 1993042.	4.6	16
32	Morphological Features Extracted by AI Associated with Spatial Transcriptomics in Prostate Cancer. <i>Cancers</i> , 2021, 13, 4837.	3.7	15
33	Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology. <i>American Journal of Surgical Pathology</i> , 2018, 42, 103-115.	3.7	14
34	Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1642-1651.	2.5	13
35	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. <i>BJU International</i> , 2022, 130, 193-199.	2.5	13
36	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 380-386.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets. <i>International Journal of Medical Informatics</i> , 2020, 133, 104014.	3.3	11
38	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. <i>Cancer Imaging</i> , 2020, 20, 72.	2.8	10
39	Detection of Prostate Cancer Using Biparametric Prostate <scp>MRI</scp>, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 465-477.	3.4	9
40	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. <i>PLoS ONE</i> , 2020, 15, e0235779.	2.5	8
41	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 263-272.	0.4	7
42	Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer. <i>Cancers</i> , 2021, 13, 628.	3.7	7
43	Exploration of Extracellular Vesicle miRNAs, Targeted mRNAs and Pathways in Prostate Cancer: Relation to Disease Status and Progression. <i>Cancers</i> , 2022, 14, 532.	3.7	7
44	Three-Dimensional Presentation of Tumor Histopathology: A Model Using Tongue Squamous Cell Carcinoma. <i>Diagnostics</i> , 2021, 11, 109.	2.6	6
45	Transcript analysis of commercial prostate cancer risk stratification panels in hardâ€œpredict grade group 2â€œ4 prostate cancers. <i>Prostate</i> , 2021, 81, 368-376.	2.3	6
46	Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 16.e1-16.e7.	1.6	5
47	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. <i>European Urology Oncology</i> , 2018, 1, 268-275.	5.4	5
48	Active surveillance versus initial surgery in the long-term management of Bosniak IIFâ€œIV cystic renal masses. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
49	Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Nonâ€œorgan-confined Pathology and Biochemical Recurrence After Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 7, 1316-1323.	3.1	4
50	Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. <i>Scientific Reports</i> , 2016, 6, 36161.	3.3	3
51	Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. <i>Scientific Reports</i> , 2021, 11, 13684.	3.3	3
52	Characteristics of Patients in SPCG-15â€œA Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. <i>European Urology Open Science</i> , 2022, 41, 63-73.	0.4	3
53	PTEN and ERG expression in MRIâ€œultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer. <i>Prostate</i> , 2020, 80, 1118-1127.	2.3	2
54	Response to Letter on use of functional imaging by 11C-metomidate PET for primary aldosteronism subtyping. <i>European Journal of Endocrinology</i> , 2021, 184, L11-L12.	3.7	2

#	ARTICLE	IF	CITATIONS
55	Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-up. <i>European Urology Focus</i> , 2022, 8, 1151-1156.	3.1	2
56	Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers. <i>Scandinavian Journal of Urology</i> , 2021, 55, 448-454.	1.0	2
57	The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, 221-221.	1.6	2
58	Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression. <i>Cancers</i> , 2022, 14, 278.	3.7	2
59	Spectral decoupling for training transferable neural networks in medical imaging. <i>IScience</i> , 2022, 25, 103767.	4.1	2
60	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. <i>Cancer Research Communications</i> , 2022, 2, 172-181.	1.7	2
61	AI Model for Prostate Biopsies Predicts Cancer Survival. <i>Diagnostics</i> , 2022, 12, 1031.	2.6	2
62	Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2019, 79, 424-430.	1.2	1
63	Fast prostate retrieval in robot-assisted laparoscopic prostatectomy for next-generation biobanking. <i>Journal of Robotic Surgery</i> , 2020, 14, 271-274.	1.8	1
64	Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? <i>Eur Urol.</i> 2017;71:838â€“40. <i>European Urology</i> , 2017, 72, e68-e69.	1.9	0
65	Correlation of endothelial angiopoietin-2 expression with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 461-461.	1.6	0
66	The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 715-727.	2.5	0
67	Title is missing!., 2020, 15, e0235779.		0
68	Title is missing!., 2020, 15, e0235779.		0
69	Title is missing!., 2020, 15, e0235779.		0
70	Title is missing!., 2020, 15, e0235779.		0
71	Abstract PR016: The spatial landscape of clonal somatic mutations in benign and malignant tissue. <i>Cancer Research</i> , 2022, 82, PR016-PR016.	0.9	0
72	Abstract 2171: The spatial landscape of clonal somatic mutations in benign and malignant tissue. <i>Cancer Research</i> , 2022, 82, 2171-2171.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Abstract 2234: Incidence of clinically significant prostate cancer after negative prostate MRI - comparison to general population. Cancer Research, 2022, 82, 2234-2234.	0.9	0
74	Abstract 5171: Gene expression in multi-parametric MRI visible and invisible prostate cancers predicts progression. Cancer Research, 2022, 82, 5171-5171.	0.9	0